BGI Genomics Company Description

BGI Genomics Co., Ltd. provides genomic sequencing and proteomic services in China and internationally.

The company offers solutions to various applications, such as basic research covering human, plant, animal, and microbial species; clinical research in human health; genetic testing and screening; drug discovery and development; and agriculture and biodiversity preservation and sustainability.

It provides DNA, RNA, and customized sequencing solutions; and mass spec services, as well as COVID-19 PCR test kits and COVID lab solutions.

In addition, the company offers diagnostics and precision medicines for COVID-19, infectious diseases, and oncology.

It serves academic institutions, pharmaceutical companies, health care providers, and other organizations.

The company was formerly known as Shenzhen BGI Medicine Co., Ltd. and changed its name to BGI Genomics Co., Ltd. in 2015.

BGI Genomics Co., Ltd. was founded in 1999 and is headquartered in Shenzhen, China. BGI Genomics Co., Ltd operates as a subsidiary of BGI Group.

BGI Genomics Co., Ltd.

Country	China
Founded	1999
Industry	Diagnostics & Research
Sector	Healthcare
Employees	3,702
CEO	Lijian Zhao

Contact Details

Address: Building No.7 Shenzhen, 518083 China
Phone	86 755 2527 3120
Website	bgi.com

Stock Details

Ticker Symbol	300676
Exchange	Shenzhen Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	CNE100003449
SIC Code	2836

Key Executives

Name	Position
Lijian Zhao	GM and Director
Yujue Wang	Chief Financial Officer, Deputy GM and Non Independent Director
Qian Xu	Director of Legal Affairs, General Counsel, Deputy GM and Secretary
Ning Li	Deputy GM and Director
Zhu Shida	Deputy GM and Non Independent Director
Weijun Chen	Deputy General Manager
Hui Liu	Head of the accounting department and Accounting Supervisor
Hao Li	Deputy GM and Head of Marketing Center and i99 Division